TD-HP628016

Rovalpituzumab(TD-HP628016) is a research-grade recombinant antibody targetingDrosophila Delta homolog 3. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q9NYJ7

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

SC0001-SCX, SC0002, 1613313-01-1

Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC).• Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629• Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer., PMID:30894499• DLL3: an emerging target in small cell lung cancer., PMID:31215500• Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study., PMID:36689692• AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer., PMID:33203642• DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms., PMID:35983951• A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo., PMID:26311731• IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models., PMID:36951942• HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors., PMID:38670552• Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)., PMID:37694295

SEC-HPLC detection for Research Grade Rovalpituzumab.　　|　SDS-PAGE for Research Grade Rovalpituzumab.　　|　Flow-cytometry using anti-human DLL3 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human DLL3 monoclonal antibody (Catalog: HP628016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.

For research use only. Not suitable for clinical or therapeutic use.